PHILADELPHIA, Sept. 23, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) reported that at the Third European Influenza Conference in Portugal (September 14-17, 2008), members of the National Institute of Infectious Diseases, Japan, reported on the expanded potential role of Ampligen(r) in preventing bird flu. The paper is entitled: “The TLR3 agonist, poly I : poly C12U (Ampligen(r)) added to influenza vaccines as a nasal adjuvant induces a wide spectrum cross-protection against different subtypes including highly pathogenic H5N1 avian influenza virus.” Ampligen(r) is an experimental therapeutic and a flagship product of Hemispherx.
